Accepted Manuscript

Title: Symptom burden profile in myelofibrosis patients with thrombocytopenia: lessons and unmet needs

Authors: Allison H. Scotch, Heidi Kosiorek, Robyn Scherber, Amylou C. Dueck, Stefanie Slot, Sonja Zweegman, Peter A.W.te Boekhorst, Suzan Commandeur, Harry Schouten, Federico Sackmann, Ana Kerguelen Fuentes, Dolores Hernández-Maraver, Heike L. Pahl, Martin Griesshammer, Frank Stegelmann, Konstanze Döhner, Thomas Lehmann, Karin Bonatz, Andreas Reiter, Francoise Boyer, Gabriel Etienne, Jean-Christophe Ianotto, Dana Ranta, Lydia Roy, Jean-Yves Cahn, Claire N. Harrison, Deepti Radia, Pablo Muxi, Norman Maldonado, Carlos Besses, Francisco Cervantes, Peter L. Johansson, Tiziano Barbui, Giovanni Barosi, Alessandro M. Vannucchi, Chiara Paoli, Francesco Passamonti, Bjorn Andreasson, Maria L. Ferrari, Alessandro Rambaldi, Jan Samuelsson, Gunnar Birgegard, Zhijian Xiao, Zefeng Xu, Yue Zhang, Xiujuan Sun, Junqing Xu, Jean-Jacques Kiladjian, Peihong Zhang, Robert Peter Gale, Ruben A. Mesa, Holly L. Geyer

PII: S0145-2126(17)30539-8
DOI: <https://doi.org/10.1016/j.leukres.2017.10.002>
Reference: LR 5845

To appear in: *Leukemia Research*

Received date: 8-7-2017
Revised date: 7-10-2017
Accepted date: 11-10-2017

Please cite this article as: Scotch Allison H, Kosiorek Heidi, Scherber Robyn, Dueck Amylou C, Slot Stefanie, Zweegman Sonja, Boekhorst Peter AWte, Commandeur Suzan, Schouten Harry, Sackmann Federico, Fuentes Ana Kerguelen, Hernández-Maraver Dolores, Pahl Heike L, Griesshammer Martin, Stegelmann Frank, Döhner Konstanze, Lehmann Thomas, Bonatz Karin, Reiter Andreas, Boyer Francoise, Etienne Gabriel, Ianotto Jean-Christophe, Ranta Dana, Roy Lydia, Cahn Jean-Yves, Harrison Claire N, Radia Deepti, Muxi Pablo, Maldonado Norman, Besses Carlos, Cervantes Francisco, Johansson Peter L, Barbui Tiziano, Barosi Giovanni, Vannucchi Alessandro M, Paoli Chiara, Passamonti Francesco, Andreasson Bjorn, Ferrari Maria

L, Rambaldi Alessandro, Samuelsson Jan, Birgegard Gunnar, Xiao Zhijian, Xu Zefeng, Zhang Yue, Sun Xiujuan, Xu Junqing, Kiladjian Jean-Jacques, Zhang Peihong, Gale Robert Peter, Mesa Ruben A, Geyer Holly L. Symptom burden profile in myelofibrosis patients with thrombocytopenia: lessons and unmet needs. *Leukemia Research* <https://doi.org/10.1016/j.leukres.2017.10.002>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Symptom burden profile in myelofibrosis patients with thrombocytopenia: lessons and unmet needs

Running Head: Symptom Burden in MF with Thrombocytopenia

Allison H. Scotch¹, Heidi Kosiorek², Robyn Scherber³, Amylou C. Dueck², Stefanie Slot⁴, Sonja Zweegman⁴, Peter AW te Boekhorst⁵, Suzan Commandeur⁶, Harry Schouten⁷, Federico Sackmann⁸, Ana Kerguelen Fuentes⁹, Dolores Hernández-Maraver⁹, Heike L. Pahl¹⁰, Martin Griesshammer¹¹, Frank Stegelmann¹², Konstanze Döhner¹², Thomas Lehmann¹³, Karin Bonatz¹⁴, Andreas Reiter¹⁴, Francoise Boyer¹⁵, Gabriel Etienne¹⁶, Jean-Christophe Iannotto¹⁷, Dana Ranta¹⁸, Lydia Roy¹⁹, Jean-Yves Cahn²⁰, Claire N. Harrison²¹, Deepti Radia²¹, Pablo Muxi²², Norman Maldonado²³, Carlos Besses²⁴, Francisco Cervantes²⁵, Peter L. Johansson²⁶, Tiziano Barbui²⁷, Giovanni Barosi²⁸, Alessandro M. Vannucchi²⁹, Chiara Paoli²⁹, Francesco Passamonti³⁰, Bjorn Andreasson²⁶, Maria L Ferrari³¹, Alessandro Rambaldi²⁷, Jan Samuelsson³², Gunnar Birgegård³³, Zhijian Xiao³⁴, Zefeng Xu³⁴, Yue Zhang³⁴, Xiujuan Sun³⁴, Junqing Xu³⁴, Jean-Jacques Kiladjian³⁵, Peihong Zhang³⁶, Robert Peter Gale³⁷, Ruben A. Mesa³⁹, and Holly L. Geyer¹

¹Department of Internal Medicine, Mayo Clinic, Scottsdale, AZ USA

²Section of Biostatistics, Mayo Clinic, Scottsdale, AZ USA

³Oregon Health and Sciences University, Portland, OR USA

⁴Department of Hematology, VU University Medical Center, Amsterdam, Netherlands

⁵Department of Hematology, Erasmus MC, Rotterdam, Netherlands

⁶Department of Dermatology, LUMC, Leiden, Netherlands

⁷Department of Hematology, MUMC, Maastricht, Netherlands

⁸Fundaleu, Buenos Aires, Argentina

⁹Department of Haematology, University Hospital La Paz, Madrid, Spain

¹⁰Department of Molecular Hematology, University Hospital Freiburg, Freiburg, Germany

¹¹Johannes Wesling Klinikum Minden, Germany

¹²Department of Internal Medicine III, University Hospital of Ulm, Germany

¹³Hematology Department, University Hospital Basel, Switzerland

¹⁴Medizinische Klinik, Universitätsmedizin Mannheim, Germany

¹⁵Centre Hospitalier Universitaire, Angers, France

¹⁶Institut Bergonie, Bordeaux, France

¹⁷Centre Hospitalier Universitaire, Brest, France

¹⁸Hospitalier Universitaire, Nancy, France

¹⁹Centre Hospitalier Universitaire, Poitiers, France

²⁰Centre Hospitalier Universitaire, Grenoble, France

²¹Dept. of Haematology, Guy's and St. Thomas NHS Foundation Trust, London, United Kingdom

²²Unidad de Hematología, Hospital Británico, Montevideo, Uruguay

²³University of Puerto Rico School of Medicine, San Juan, Puerto Rico

²⁴Hematology Department, Hospital del Mar, Barcelona, Spain

²⁵Hematology Department, Hospital Clínic, IDIBAPS, University of Barcelona, Spain

²⁶Internal Medicine, NU Hospital Organization, Uddevalla, Sweden

²⁷Unit of Hematology, Ospedali Riuniti di Bergamo, Bergamo, Italy

²⁸Lab. of Clinical Epidemiology, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy

²⁹Hematology, Dept of Medical and Surgical Care, University of Florence, Florence, Italy

³⁰Department of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy

³¹Biol. Sci., Ospedali Riuniti di Bergamo, Bergamo, Italy

³²Department of Internal Medicine, Stockholm South Hospital, Stockholm, Sweden

³³Dept. of Hematology, University Hospital, Uppsala, Sweden

³⁴MDS and MPN Centre, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China

³⁵Clinical Investigation Center, Hopital Saint-Louis, Paris, France

³⁶Department of Pathology, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China

³⁷Imperial College, London, UK

³⁸Department of Hematology and Oncology, Mayo Clinic, Scottsdale, AZ USA

Correspondence: Holly Geyer, MD, Mayo Clinic, 13400 E Shea Blvd., Scottsdale, AZ USA 85259; e-mail: geyer.holly@mayo.edu. Phone: 480-301-8000.

Word Count (Text): 2,316

HIGHLIGHTS

- Symptom burden in myelofibrosis patients was assessed via the MPN-SAF and MPN-10.
- Thrombocytopenic patients had higher individual and total symptom scores.
- Severely thrombocytopenic patients had different clinical features but similar QOL.
- MF patients with thrombocytopenia may benefit from therapy to decrease symptoms.

Word Count (

Abstract): 199

Tables: 3

Figures: 4

ABSTRACT

Myelofibrosis is a myeloproliferative neoplasm associated with progressive cytopenias and high symptom burden. MF patients with thrombocytopenia have poor prognosis but the presence of thrombocytopenia frequently precludes the use of JAK2 inhibitors. In this study, we assessed quality of life and symptom burden in 418 MF patients with (n=89) and without (n=329) thrombocytopenia using prospective data from the MPN-QOL study group database, including the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) and Total Symptom Score (MPN10). Thrombocytopenia, defined as platelet count $<100 \times 10^9/L$ (moderate $51-100 \times 10^9/L$; severe $\leq 50 \times 10^9/L$), was associated with anemia (76% vs. 45%, $p<0.001$), leukopenia (29% vs. 11%, $p<0.001$), and need for red blood cell transfusion (35% vs. 19%, $p=0.002$). Thrombocytopenic patients had more fatigue, early satiety, inactivity, dizziness, sad mood, cough, night sweats, itching, fever, and weight loss; total symptom scores were also higher (33 vs. 24, $p<0.001$). Patients with severe thrombocytopenia were more likely to have anemia (86% vs. 67%, $p=0.04$), leukopenia (40% vs. 20%, $p=0.04$), and transfusion requirements (51% vs. 20%, $p=0.002$) but few differences in symptoms when compared to patients with moderate thrombocytopenia. These results suggest that MF patients with thrombocytopenia experience greater symptomatic burden than MF patients without thrombocytopenia and may benefit from additional therapies.

Keywords: myeloproliferative neoplasm; myelofibrosis; thrombocytopenia; quality of life; symptomatology

INTRODUCTION

Myelofibrosis (MF) is a clonally derived Philadelphia chromosome negative myeloproliferative neoplasm (MPN) associated with progressive cytopenias and potential to transform into acute myelogenous leukemia (AML). MPNs are often associated with dysregulated signaling of the Janus kinase-signal transducers and activators of transcription (JAK-STAT) pathway. The most common somatic mutation, JAK2 V617F, occurs in 50-60% of patients with MF (1-3).

MF patients exhibit a high degree of symptomatology with potentially dramatic impacts on quality of life (QOL). Common symptoms include abdominal pain, bone pain, fatigue, pruritus, night sweats, fever, and weight loss (4). Cytopenic derangements are common and closely linked to disease progression. In particular, thrombocytopenia is a proven negative prognostic indicator and predictor of transformation to AML (5). MF patients with platelets under $50 \times 10^9/L$ have more frequent anemia and leukopenia and higher rates of both hemorrhagic and thrombotic complications compared to MF patients with higher platelet counts (6).

Treatment options are limited for patients with thrombocytopenia. Ruxolitinib, a JAK1/JAK2 inhibitor, was shown in the phase III COMFORT-I (7) and COMFORT-II (8) trials to have significant symptomatic benefit in intermediate-2 or high risk MF patients with platelets of at least $100 \times 10^9/L$. However, the drug may paradoxically contribute to thrombocytopenia and is presently only indicated in patients with platelets of at least $50 \times 10^9/L$.

To date, no investigation has evaluated the correlations between patient symptomatology and platelet count. In this study, we aimed to characterize the symptom burden in MF patients with and without thrombocytopenia using prospectively collected quality of life data. We also assessed differences in clinical characteristics and symptomatology among patients with varying degrees of thrombocytopenia.

METHODS

Patient Selection

This study was approved by the Institutional Review Board (IRB) of the Mayo Clinic. Data were prospectively collected from an international pool of MPN patients recruited from academic, private practice, and government-funded centers. A total of 418 patients were included in the study; all had a diagnosis of MF. Patients completed the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF), Brief Fatigue Inventory (BFI), and European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) via self-reporting. All surveys were completed in the patients' native language (English, German, Dutch, French, Spanish, Italian, Chinese, and Swedish) and translated to English using standard PRO translational methods. Clinical information was also gathered at the time of survey collection and included laboratory information, treatment history, prognostic scoring, and physical examination results as assessed by clinicians.

In this study, thrombocytopenia was defined as a platelet count less than $100 \times 10^9/L$, anemia was defined as hemoglobin less than 11 g/dL, and leukopenia was defined as a white blood cell (WBC) count less than $3.5 \times 10^9/L$. Moderate thrombocytopenia was defined as a platelet count of $51-100 \times 10^9/L$, and severe thrombocytopenia was defined as a platelet count less than or equal to $50 \times 10^9/L$. A broader categorization of patients with "lab abnormality" included any patient who met criteria for anemia, leukopenia, or thrombocytopenia.

Symptom Evaluation

Symptom evaluation was performed using the previously validated MPN-SAF (9). All participants were required to complete at least six of the ten MPN-SAF symptom questions to meet study inclusion criteria. Symptoms were scored on a scale from 0 (absent/as good as it can be) to 10 (worst imaginable/as bad as it can be), and items specifically assessed quality of life

(QOL), early satiety, abdominal pain or discomfort, inactivity, headache, difficulty with concentration, dizziness, numbness, insomnia, sad mood, difficulty with sexual desire or function, cough, night sweats, itching, bone pain, fever, and weight loss. Total symptom score (TSS) was calculated by multiplying the average score across items by ten to achieve a 0-100 scaled score. The MD Anderson BFI was used to assess worst fatigue rating (10). Splenomegaly was assessed by clinicians based on physical examination and reported as an estimated value in centimeters.

Prognostic Scoring

The Dynamic International Prognostic Scoring System (DIPSS) was used to calculate MF prognostic scores (11). Patients were stratified into low risk (0 points), intermediate-1 risk (1-2 points), intermediate-2 risk (3-4 points), and high risk (>4 points) using the following scoring variables: circulating blasts greater than or equal to 1% (1 point), constitutional symptoms (1 point), age greater than 65 years (1 point), WBC count greater than or equal to $25 \times 10^9/L$ (1 point), and hemoglobin less than 11 g/dL (2 points).

Statistical Analysis

Demographics, clinical variables, and symptom scores were compared between subgroups of MF patients with and without thrombocytopenia using analysis of variance (ANOVA) F-tests for continuous variables or Chi-squared tests for discrete data. Comparisons between patients with severe and moderate thrombocytopenia were done similarly. Statistical significance was set at $p < 0.05$. All statistical analyses were conducted using SAS software version 9.4 (SAS Inc., Cary, NC).

RESULTS

Demographic and Clinical Characteristics

A total of 418 MF patients with (n=89) and without (n=329) thrombocytopenia completed the MPN-SAF and BFI. Patients with thrombocytopenia were further classified as having moderate (n=46) or severe (n=43) thrombocytopenia. Demographic and clinical characteristics are shown in Tables 1 and 2. Mean age overall was 60.2 (SD=12.3) years and 47.4% of patients were male. Most patients had a diagnosis of primary myelofibrosis (69.4%) and met intermediate-1 DIPSS risk criteria (54.9%). Anemia (51.6%) and laboratory abnormalities (62.4%) were common. However, most patients had no history of prior thrombosis (11.3%), prior hemorrhage (5.1%), or RBC transfusion requirements (22.5%).

Total Symptom Scores (TSS) stratified by presence or absence of clinical and lab abnormalities are shown in Table 3. Patients with anemia ($p<0.001$), any lab abnormality ($p<0.001$), those requiring RBC transfusion ($p=0.003$), and those with higher DIPSS risk scores ($p<0.001$) reported significantly higher TSS. There was no significant association between leukopenia and overall symptom burden as reported by TSS, though a trend toward high TSS in patients with leukopenia was observed.

Overall, the highest symptom scores in this cohort were reported for worst fatigue (4.8/10), sexuality (4.3/10), overall compromise in QOL (3.4/10), and inactivity (3.2/10). In contrast, lowest scores were reported for fever (0.6/10), cough (1.6/10), abdominal pain (1.7/10), and headache (1.7/10).

Impact on Symptoms and Phenotype: Thrombocytopenia vs. No Thrombocytopenia

Patient demographics, clinical features, prognostic scores, and MPN-SAF and BFI results including symptom scores (Figure 1) and prevalence (Figure 2) were compared among MF patients with and without thrombocytopenia. Overall, patients with thrombocytopenia were slightly younger (57.4 vs. 61.0 years, $p=0.01$), had longer disease duration (11.9 vs. 8.8 years, $p=0.05$), had more RBC transfusion requirements (34.8% vs. 19.1%, $p=0.002$), were more likely to have

PMF (82% vs. 66%, $p=0.01$), and had more laboratory abnormalities including anemia (76.4% vs. 44.8%, $p<0.001$) and leukopenia (29.2% vs. 10.6%, $p<0.001$). Patients with thrombocytopenia did not differ from patients without thrombocytopenia by DIPSS risk score, gender, history of prior thrombosis, or prior hemorrhage (Table 1).

Patients with thrombocytopenia experienced significantly worse symptom burden in comparison to patients without thrombocytopenia with higher symptoms scores for worst fatigue (5.6 vs. 4.6, $p=0.002$), inactivity (4.4 vs. 2.9, $p<0.001$), impaired overall QOL (4.3 vs. 3.1, $p<0.001$), dizziness (3.2 vs 2.4, $p=0.046$), sad mood (3.8 vs. 2.5, $p<0.001$), cough (2.2 vs. 1.4, $p=0.003$), night sweats (3.4 vs. 2.6, $p=0.02$), itching (2.9 vs. 1.8, $p=0.001$), fever (0.9 vs. 0.5, $p=0.04$), weight loss (3.3 vs. 1.9, $p<0.001$), and early satiety (3.8 vs. 2.9, $p=0.01$); see Figure 1. Overall TSS was also significantly higher (32.8 vs. 24.1, $p<0.001$) in patients with thrombocytopenia. There were no differences in abdominal discomfort, abdominal pain, bone pain, headache, poor concentration, sexual dysfunction, numbness, or insomnia. With regard to prevalence of symptoms, weight loss (72.1% vs. 41.3%, $p<0.001$) and decline in overall QOL (90.8% vs. 81.9%, $p=0.045$) were seen with significantly higher frequency in the thrombocytopenic group compared to MF patients without thrombocytopenia; see Figure 2.

Impact on Symptoms and Phenotype: Moderate vs. Severe Thrombocytopenia

Patient demographics, clinical features, prognostic scores, and MPN-SAF and BFI results were compared between MF patients with moderate (platelets $51-100 \times 10^9/L$) and severe (platelets $<50 \times 10^9/L$) thrombocytopenia. As seen in Table 2, patients with severe thrombocytopenia were more likely to have anemia (86.0% vs. 67.4%, $p=0.04$), leukopenia (39.5% vs. 19.6%, $p=0.04$), and require RBC transfusions (51.2% vs. 19.6%, $p=0.002$). Patients did not differ by MF subtype, age, gender, history of prior thrombosis, prior hemorrhage, DIPSS risk scores, or mean MPN duration. No differences were noted in individual or total symptom

scores between groups (Figure 3, Figure 4) with one exception; patients with severe thrombocytopenia experienced less frequent sad mood (60.5% vs. 82.2%, $p=0.02$).

DISCUSSION

As a group, myelofibrosis patients experience a high symptom burden affecting quality of life. In this analysis, we demonstrate that MF patients with thrombocytopenia exhibit an even greater symptom burden, as well as distinct clinical characteristics, when compared to MF patients without thrombocytopenia. Several important symptoms were both more prevalent and more severe in MF patients with thrombocytopenia including fatigue, inactivity, early satiety, and impaired quality of life. In accordance with this, the total symptom score was also significantly higher. Notably, there do appear to be some symptom clusters for which there are no major differences between MF patients with and without thrombocytopenia. These include symptoms related to abdominal complaints (pain, discomfort), neurological issues (headache, poor concentration, numbness, insomnia), or extramedullary hematopoiesis (bone pain, abdominal pain).

Interestingly, data from this study do not demonstrate a significant association between DIPSS risk category and either presence or degree of thrombocytopenia, despite the fact that thrombocytopenia is a known risk factor for disease advancement. In fact, the DIPSS Plus score, an updated version of the DIPSS scoring system, includes platelet count in its calculation (5). While we did observe a trend toward patients with lower platelet counts having higher DIPSS scores, this did not reach statistical significance. This may be because other clinical factors included in the DIPSS score such as age did not differ significantly between study groups, thus diluting the effect of thrombocytopenia or other laboratory abnormalities. The fact that thrombocytopenic patients experience a high degree of symptoms despite them not being in a higher risk category suggests that clinical risk score is not necessarily an accurate surrogate for symptom burden or quality of life for MF patients. This aligns with previously published data

suggesting that high symptom burden can be seen even in patients with lower clinical risk scores due to significant heterogeneity of symptomatology within MF and other MPN subtypes (12).

In this study, patients with thrombocytopenia were no more likely to have a history of thrombosis or hemorrhage than patients without thrombocytopenia. This is supported by other literature suggesting that low platelet counts in this population do not necessarily correlate with risk for bleeding complications (13). Additionally, some data have shown that MF patients with lower platelet counts at diagnosis actually have a higher risk for arterial, venous, and total thrombotic events (14, 15). This likely because thrombocytopenia is associated with more advanced disease and higher degrees of inflammation and is therefore seen in association with thrombosis. In addition, cytoreductive therapy to control thrombocytosis does not necessarily result in decreased risk for thrombosis (16).

Of note, in this study abdominal pain and discomfort were two of the few symptoms that were not rated as more severe in thrombocytopenic patients with MF as compared to patients with normal platelet counts. This is somewhat surprising, as thrombocytopenic MF patients frequently experience splenomegaly due to both extramedullary hematopoiesis and splenic platelet sequestration. This in turn can cause abdominal symptomatology that negatively impacts QOL. The fact that these symptoms were not reported to a high degree in this study population suggests that bone marrow failure more than splenic sequestration may be the underlying cause of thrombocytopenia in this patient group. In addition, the lack of symptom differences between the moderate and severe thrombocytopenia groups indicates that symptom burden may not be related directly to low platelet counts, but rather to the underlying bone marrow failure and its sequelae that are seen in the more advanced disease states characteristic of these patients. In short, the utility of platelet count as a clinical indicator of disease status and burden is at least in part related to its role as a marker of adequate bone marrow function for MF patients.

While treatment options for MF patients with thrombocytopenia have been limited due to risk of exacerbating cytopenias, more recent data indicate that judicious use of ruxolitinib in this group can be both safe and clinically effective. An interim analysis of the phase III COMFORT-I and -II trials evaluating the subset of MF patients with platelet counts of $50\text{-}100 \times 10^9/\text{L}$ found that more than half of patients achieved stable dosing and demonstrated an average 24% reduction in spleen volume and 44% reduction in TSS (17). Similarly, the first post-market analysis of ruxolitinib showed that patients with platelets under $100 \times 10^9/\text{L}$ experienced improvement in symptom burden and a decrease in splenomegaly with only minimal decline in platelet count and no serious bleeding complications (18). Successful use of ruxolitinib, even in patients with severe thrombocytopenia, has also been reported with minimal adverse effects (19).

Pacritinib, an inhibitor of both JAK2 and Fms-related tyrosine kinase 3 (FLT3), has also been tested in phase III trials that included patients with baseline cytopenias. The PERSIST-1 trial demonstrated that pacritinib reduces MF symptom burden even amongst patients with baseline thrombocytopenia (20). The PERSIST-2 trial specifically evaluated pacritinib in MF patients with platelets less than $100 \times 10^9/\text{L}$, including those who previously received ruxolitinib, and found it be more effective than best available therapy at inducing spleen volume reduction and decreasing TSS (21).

ACKNOWLEDGEMENTS

The authors wish to acknowledge the patients, families, and clinicians whose participation made this research possible. All research was funded by internal grant funding.

Given the high symptomatic burden in this population, these data support a paradigm where MF patients with thrombocytopenia can be reasonably considered for targeted therapies. While there is some risk of lowering platelet count further or exacerbating concomitant cytopenias in this setting, there is now evidence that with close monitoring these patients can be safely treated in many cases. In conclusion, the results of this study demonstrate that MF patients with thrombocytopenia face a significant symptom burden and are likely to benefit from close surveillance of their symptomatology while receiving consideration for additional therapies.

REFERENCES

1. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. *Lancet (London, England)*. 2005;365(9464):1054-61.
2. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. *The New England journal of medicine*. 2005;352(17):1779-90.
3. Zhao ZJ, Vainchenker W, Krantz SB, Casadevall N, Constantinescu SN. Role of tyrosine kinases and phosphatases in polycythemia vera. *Seminars in hematology*. 2005;42(4):221-9.
4. Mesa RA, Niblack J, Wadleigh M, Verstovsek S, Camoriano J, Barnes S, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international Internet-based survey of 1179 MPD patients. *Cancer*. 2007;109(1):68-76.
5. Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, et al. DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. *J Clin Oncol*. 2011;29(4):392-7.
6. Hernandez-Boluda JC, Correa JG, Alvarez-Larran A, Ferrer-Marin F, Raya JM, Martinez-Lopez J, et al. Clinical characteristics, prognosis and treatment of myelofibrosis patients with severe thrombocytopenia. *Br J Haematol*. 2017.
7. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. *The New England journal of medicine*. 2012;366(9):787-98.

8. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. *The New England journal of medicine*. 2012;366(9):799-807.
9. Scherber R, Dueck AC, Johansson P, Barbui T, Barosi G, Vannucchi AM, et al. The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients. *Blood*. 2011;118(2):401-8.
10. Mendoza TR, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, et al. The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. *Cancer*. 1999;85(5):1186-96.
11. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira A, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). *Blood*. 2010;115(9):1703-8.
12. Geyer HL, Scherber RM, Dueck AC, Kiladjian JJ, Xiao Z, Slot S, et al. Distinct clustering of symptomatic burden among myeloproliferative neoplasm patients: retrospective assessment in 1470 patients. *Blood*. 2014;123(24):3803-10.
13. Kander EM, Raza S, Zhou Z, Gao J, Zakarija A, McMahon BJ, et al. Bleeding complications in BCR-ABL negative myeloproliferative neoplasms: prevalence, type, and risk factors in a single-center cohort. *International journal of hematology*. 2015;102(5):587-93.
14. Buxhofer-Ausch V, Gisslinger H, Thiele J, Gisslinger B, Kvasnicka HM, Mullauer L, et al. Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined

early/prefibrotic myelofibrosis: an international study of 264 patients. *Am J Hematol*. 2012;87(7):669-72.

15. Schwarz J, Penka M, Ovesna P, Cerna O, Brychtova Y, Dulicek P. Thrombosis in MPN with Thrombocythemia Is Associated with Higher Platelet Count At the Time of the Event: Data From the Czech Registry of Patients Treated with Anagrelide. *Blood*. 2011;118(21):3857.

16. Palandri F, Catani L, Testoni N, Ottaviani E, Polverelli N, Fiacchini M, et al. Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapy. *Am J Hematol*. 2009;84(4):215-20.

17. Talpaz M, Paquette R, Afrin L, Hamburg SI, Prchal JT, Jamieson K, et al. Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts. *Journal of hematology & oncology*. 2013;6(1):81.

18. Geyer H, Cannon K, Knight E, Fauble V, Camoriano J, Emanuel R, et al. Ruxolitinib in clinical practice for therapy of myelofibrosis: single USA center experience following Food and Drug Administration approval. *Leuk Lymphoma*. 2014;55(1):195-7.

19. Bjorn ME, Holmstrom MO, Hasselbalch HC. Ruxolitinib is manageable in patients with myelofibrosis and severe thrombocytopenia: a report on 12 Danish patients. *Leuk Lymphoma*. 2016;57(1):125-8.

20. Mesa RA, Vannucchi AM, Mead A, Egyed M, Szoke A, Suvorov A, et al. Pacritinib versus best available therapy for the treatment of myelofibrosis irrespective of baseline cytopenias (PERSIST-1): an international, randomised, phase 3 trial. *The Lancet Haematology*. 2017;4(5):e225-e36.

21. Mascarenhas J, Hoffman R, Talpaz M, Gerds AT, Stein B, Gupta V, et al. Results of the Persist-2 Phase 3 Study of Pacritinib (PAC) Versus Best Available Therapy (BAT), Including Ruxolitinib (RUX), in Patients (pts) with Myelofibrosis (MF) and Platelet Counts <100,000/ μ l. Blood. 2016;128(22):LBA-5.

Table 1.

Demographics and clinical characteristics of MF patients with and without thrombocytopenia

	Normal (Plt >100x10 ⁹ /L) <i>n</i> =329	Thrombocytopenia (Plt <100x10 ⁹ /L) <i>n</i> =89	Total <i>n</i> =418	<i>p</i>-value
Age (mean, SD)	61.0 (12.15)	57.4 (12.67)	60.2 (12.34)	0.01
Gender (male)	156 (47.4%)	42 (47.2%)	198 (47.4%)	0.97
MF subtype				0.01
Primary MF	217 (66%)	73 (82%)	290 (69.4%)	
ET-MF	64 (19.5%)	7 (7.9%)	71 (17%)	
PV-MF	48 (14.6%)	9 (10.1%)	57 (13.6%)	
DIPSS risk				0.07
Low	38 (19.3%)	5 (13.9%)	43 (18.5%)	
Intermediate-1	113 (57.4%)	15 (41.7%)	128 (54.9%)	
Intermediate-2	41 (20.8%)	14 (38.9%)	55 (23.6%)	
High	5 (2.5%)	2 (5.6%)	7 (3%)	
Anemia (Hgb <11g/dL)	147 (44.8%)	68 (76.4%)	215 (51.6%)	<0.001
Leukopenia (WBC <3.5 x10 ⁹ /L)	35 (10.6%)	26 (29.2%)	61 (14.6%)	<0.001
Lab abnormality	172 (52.3%)	89 (100%)	261 (62.4%)	<0.001
Prior thrombosis	42 (12.9%)	5 (5.6%)	47 (11.3%)	0.06
Prior hemorrhage	14 (4.3%)	7 (7.9%)	21 (5.1%)	0.17
Required RBC transfusion	62 (19.1%)	31 (34.8%)	93 (22.5%)	0.002
Mean MPN duration (years, SD)	8.8 (8.33)	11.9 (10.86)	9.3 (8.81)	0.049

DIPSS, Dynamic International Prognostic Scoring System; ET, essential thrombocythemia; Hgb, hemoglobin; MF, myelofibrosis; Plt, platelets; PV, polycythemia vera; RBC, red blood cell; SD, standard deviation; WBC, white blood cell

Table Legend

Table 2.

Demographics and clinical characteristics of MF patients with moderate and severe thrombocytopenia

	Moderate Thrombocytopenia (Plt 51-100x10 ⁹ /L) <i>n</i> =46	Severe Thrombocytopenia (Plt <50x10 ⁹ /L) <i>n</i> =43	Total <i>n</i> =89	<i>p</i>-value
Age (mean, SD)	57.9 (11.29)	56.9 (14.11)	57.4 (12.67)	0.72
Gender (male)	21 (45.7%)	21 (48.8%)	42 (47.2%)	0.76
MF subtype				0.87
Primary MF	38 (82.6%)	35 (81.4%)	73 (82%)	
ET-MF	4 (8.7%)	3 (7%)	7 (7.9%)	
PV-MF	4 (8.7%)	5 (11.6%)	9 (10.1%)	
DIPSS risk				0.09
Low	4 (21.1%)	1 (5.9%)	5 (13.9%)	
Intermediate-1	10 (52.6%)	5 (29.4%)	15 (41.7%)	
Intermediate-2	5 (26.3%)	9 (52.9%)	14 (38.9%)	
High	0 (0%)	2 (11.8%)	2 (5.6%)	

Anemia (Hgb <11g/dL)	31 (67.4%)	37 (86.0%)	68 (76.4%)	0.04
Leukopenia (WBC <3.5 x10 ⁹ /L)	9 (19.6%)	17 (39.5%)	26 (29.2%)	0.04
Lab abnormality	46 (100%)	43 (100%)	89 (100%)	
Prior thrombosis	2 (4.3%)	3 (7%)	5 (5.6%)	0.59
Prior hemorrhage	2 (4.3%)	5 (11.6%)	7 (7.9%)	0.20
Required RBC transfusion	9 (19.6%)	22 (51.2%)	31 (34.8%)	0.002
Mean MPN duration (years, SD)	12.3 (12.52)	11.5 (8.58)	11.9 (10.86)	0.83
DIPSS, Dynamic International Prognostic Scoring System; ET, essential thrombocythemia; Hgb, hemoglobin; MF, myelofibrosis; Plt, platelet; PV, polycythemia vera; RBC, red blood cell; SD, standard deviation; WBC, white blood cell				

Table 3.

Associations between clinical characteristics and MPN-SAF Total Symptom Score in MF patients

	Total Symptom Score (TSS) (mean, SD) <i>n=418</i>	<i>p-value</i>
Anemia (Hgb <11 g/dL)		<i><0.001</i>
Yes	29.6 (18.4)	

No	22.3 (15.6)	
Leukopenia (WBC <3.5x10 ⁹ /L)		<i>0.06</i>
Yes	29.9 (19.3)	
No	25.3 (17.1)	
Lab abnormality		<i><0.001</i>
Yes	28.7 (18.1)	
No	21.5 (15.6)	
Required RBC transfusion		<i>0.003</i>
Yes	30.8 (19.0)	
No	24.6 (16.8)	
DIPSS risk		<i><0.001</i>
Low	15.2 (11.1)	
Intermediate-1	23.3 (15.4)	
Intermediate-2 / High	31.5 (17.1)	
DIPSS, Dynamic International Prognostic Scoring System; Hgb, hemoglobin; MF, myelofibrosis; RBC, red blood cell; SD, standard deviation; WBC, white blood cell

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure Legend

Figure 1.

Thrombocytopenia versus no thrombocytopenia by individual MPN-SAF score

Figure 2.

Thrombocytopenia versus no thrombocytopenia by individual MPN-SAF symptom prevalence

Figure 3.

Moderate versus severe thrombocytopenia by individual MPN-SAF score

Figure 4.

Moderate versus severe thrombocytopenia by individual MPN-SAF symptom frequency